Related references
Note: Only part of the references are listed.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
Chih-Cheng Lai et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
Yaseen M. Arabi et al.
TRIALS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Hongzhou Lu
BIOSCIENCE TRENDS (2020)
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
Zhenwei Wang et al.
BIOSCIENCE TRENDS (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
Yan-Rong Guo et al.
MILITARY MEDICAL RESEARCH (2020)
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors
P Panagopoulos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
Share Paper
